

# SINGAPORE MEDICAL GROUP LIMITED

(Company Registration No.: 200503187W)

---

## PROPOSED RENOUNCEABLE NON-UNDERWRITTEN RIGHTS ISSUE RECEIPT OF LISTING AND QUOTATION NOTICE

---

### 1. INTRODUCTION

The Board of Directors (the "**Board**") of Singapore Medical Group Limited (the "**Company**") refers to the Company's announcement dated 1 March 2018 (the "**Earlier Announcement**") in relation to the proposed Rights Issue.

All capitalised terms used and not defined herein shall have the same meanings given to them in the Earlier Announcement.

Further to the Earlier Announcement, the Board wishes to announce that, in relation to the proposed Rights Issue, the Company intends to issue up to 23,341,800 new ordinary shares in the issued share capital of the Company (the "**Rights Shares**" and each a "**Rights Share**") at an issue price of S\$0.48 for each Rights Share, on the basis of one (1) Rights Share for every twenty (20) existing ordinary shares in the issued share capital of the Company held by Entitled Shareholders as at a time and date to be determined by the Directors for the purposes of determining the provisional allotments of Entitled Shareholders under the proposed Rights Issue.

### 2 RECEIPT OF LISTING AND QUOTATION NOTICE

Further to the Earlier Announcement, the Board is pleased to announce that the Company has, on 8 May 2018, received the listing and quotation notice ("**LQN**") from the SGX-ST for the listing and quotation of up to 23,341,800 Rights Shares on the Catalist, subject to the following conditions:

- (a) Compliance with the SGX-ST's listing requirements; and
- (b) Shareholders' approval for the proposed Rights Issue is obtained at an EGM to be convened.

A circular containing, amongst other things, the notice of EGM and the details of the Rights Issue will be despatched to Shareholders in due course.

The LQN is not to be taken as an indication of the merits of the proposed Rights Issue, the Rights Shares, the Company, its subsidiaries and their securities. The Company will make the necessary announcement(s) on the proposed Rights Issue as appropriate or when there are further developments on the same.

### By Order of the Board

Dr Beng Teck Liang  
Executive Director and Chief Executive Officer

9 May 2018

*This Announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch (the "**Sponsor**"), for compliance with the Catalist Rules. The Sponsor has not independently verified the contents of this Announcement.*

*This Announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this Announcement, including the correctness of any of the statements or opinions made or reports contained in this Announcement.*

*The contact person for the Sponsor is Mr Eric Wong, Director, Investment Banking, Singapore. The contact particulars are 50 Raffles Place #09-01, Singapore Land Tower, Singapore 048623, Telephone: +65 6337 5115.*